Company intelligence / Profile preview

KHAN Technology Transfer Fund

Dortmund, North Rhine-Westphalia, Germany

Ownership: Private
Development stage: Other

Overview

KHAN Technology Transfer Fund I and II are early-stage life sciences venture funds that finance and co-develop drug discovery projects and spin-offs from European academia, focusing on first-in-class therapeutics at discovery, pre-clinical and early clinical stages, particularly via the Lead Discovery Center, but they are not themselves a therapeutic product company.

Therapeutic areas: OncologyCardiovascularOther
Modalities: Small moleculeMonoclonal antibodyAntibodyBiologic
Industry: Investors

Partnerships

Max Planck Society/Max Planck InnovationLead Discovery CenterEuropean Investment FundAustria WirtschaftsserviceMax Planck FoundationBoehringer Ingelheim Venture Fund (via co-developed EvlaBio asset)

Beyond the preview

Go deeper on KHAN Technology Transfer Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KHAN Technology Transfer Fund.

Explore the full profile